Skip to Content

Kineta and Rosa form strategic alliance for next stage of clinical development of lead drug candidate Shk-186

SEATTLE, WA, June 14, 2013 - Kineta, Inc. a biotechnology company focused on the development of novel modulating drugs for critical disease areas, announced today a strategic alliance with Rosa & Co. LLC (, a drug development advisory firm. The goal of the alliance will be to create pharmacokinetic/pharmacodynamics (PK/PD) models of Kineta's lead drug compound Shk-186 and estimate optimal dose and dose frequency for humans in preparation for upcoming multi-dose clinical trials.  Shk-186 is a novel, immune-sparing targeted therapeutic focused on autoimmune diseases. The drug's mechanism of action was also recently identified to have potential in enhancing metabolic activity and reducing obesity and metabolic syndrome in mice in a University of California at Irvine study.  A Phase 1 safety clinical trial of Shk-186 in humans was successfully completed earlier this year.

"This partnership will allow Kineta to incorporate Rosa's innovative PK/PD modeling and dose simulation capabilities  into our drug development process and accelerate the development of Shk-186 to potentially treat a variety of unmet medical needs," said Shawn P. Iadonato, Kineta's Executive Vice President and Chief Scientific Officer.

"Our strategic collaboration with Kineta, one of the leading emerging biotechnology companies in the industry, is powerful because it combines our unique modeling and simulation operations with their unique asset sourcing, development and financing structures," said Ron Beaver, PhD, Rosa's Founder, Chairman and CEO.

Kineta, Inc. is a Seattle-based privately held biotechnology company specializing in clinical advancement of novel drug candidates derived from leading edge scientific research.  Our world class scientists are pioneers in developing life-changing classes of new drugs designed to be more effective and safer than current medicines.  Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases and from severe pain.  Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones.  For more information on Kineta, Inc. visit our website,

Dan Eramian

About Rosa
Rosa informs its customer's most critical decisions - from preclinical through clinical development - with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD(tm) models.  With these approaches, Rosa's clients collaborate in model creation and testing, retain the final model, and acquire the ability to use and interpret it. Rosa's staff have unparalleled experience in drug-disease modeling and simulation (M&S), spanning hundreds of applications and dozens of clients over close to two decades of professional experience. Rosa is unique in their breadth and depth of disease area experience, including metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory, and antibacterials/antivirals. For more information, visit  

Sharan Pagano, Vice President, Scientific Alliances

Posted: June 2013